Accentia BioPharmaceuticals, Inc. and Exaeris, Inc. Sign Co-Promotion Agreement for MD Turbo(TM)

TEAMM Pharmaceuticals, Inc., the specialty
pharmaceutical division of Accentia BioPharmaceuticals, Inc.
(NASDAQ:ABPI), and Exaeris, Inc., the wholly owned subsidiary of Inyx,
Inc. (OTC:BB:IYXI), announced today that they have finalized a
co-promotion agreement through which the companies will co-market the
MD Turbo(TM), a novel breath-activated, dose-counting companion to
meter dose inhalers (MDIs). MD Turbo will be available by prescription
in the U.S. later this quarter.
   MD Turbo is the first commercialized product specifically designed
to coordinate inspiration and MDI activation using patented
i-Point(TM) technology. The technology enables the majority of the
MDIs used today to trigger their delivery through breath-activation,
helping ensure the labeled dose is delivered at the appropriate time.
The product contains an electronic dose counter to help patients
improve medication compliance by tracking the number of doses
remaining before a refill is required. The combination of the two key
features - breath activation and dose counting - addresses two of the
biggest challenges in MDI use.
   There are more than 40 million MDI prescriptions written annually
in the United States for the treatment of asthma and chronic
obstructive pulmonary disease (COPD). Inhalers deliver the drug
directly into the lungs, but the currently available products rely
upon a patient's precise coordination of inhaler activation and
inhalation. Studies have shown that over 50% of patients incorrectly
time the release of medication from these traditional
inhalers.(1,2,3)
   MD Turbo's breath activation and electronic dose counting is
intended to make the use of MDIs easier and more accurate for asthma
and COPD patients of all ages.
   Gary Cantrell, Executive Vice President of Sales and Marketing for
TEAMM commented: "We see tremendous synergies between TEAMM and
Exaeris, and we are delighted to have Exaeris as a partner on this
important launch. We recognized early in our planning process that MD
Turbo was going to fulfill an unmet and critical need for asthmatic
and COPD patients, and we needed to get our message out to the
appropriate healthcare professionals. Impressed with the respiratory
specialty company that Exaeris had built, we realized that the
combination of Exaeris and TEAMM's sales forces would allow us to
reach the majority of physicians and healthcare professionals
currently treating asthmatic and COPD patients. With this agreement,
our partnership has been officially established, and we look forward
to a long relationship with Exaeris."
   Stephen Beckman, President of Exaeris, added: "Exaeris' corporate
mission is to help improve outcomes for the treatment of respiratory
diseases. MD Turbo is an exciting addition to our product mix and one
that will satisfy a well-defined need in the marketplace. The
partnership with TEAMM ensures that the appropriate level of product
awareness, patient education and customer support will reach the
individuals who will benefit most from the product. We are delighted
to be associated with TEAMM in this endeavor."

   (1) Pederson S, Frost L, Arnfred T. Errors in inhalation technique
and efficiency in inhaler use in asthmatic children. Allergy. 1986;46:
118-124.

   (2) Crompton GK. Problems patients have using pressurized aerosol
inhalers. Eur J Respir Dis. 1982;63(suppl 119):101-104.

   (3) Chapman KR, Love L, Brubaker H. A comparison of
breath-actuated and conventional metered-dose inhaler inhalation
techniques in elderly subjects. Chest.1993;104(5):1332-1336.

   About Accentia Biopharmaceuticals, Inc.

   Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of late-stage
clinical products in the therapeutic areas of respiratory disease and
oncology. Two of these products are SinuNase(TM) and BiovaxID(TM). The
Company's SinuNase product, in development to treat chronic sinusitis
(rhinosinusitis), is a novel application and formulation of a known
anti-fungal licensed from the Mayo Foundation for Medical Education
and Research. BiovaxID is a patient-specific anti-cancer vaccine
focusing on the treatment of follicular non-Hodgkin's lymphoma.
BiovaxID, which is being developed by Accentia's subsidiary Biovest
International, Inc., is currently in a Phase 3 clinical trial. In
addition, Accentia's growing specialty pharmaceutical business, TEAMM
Pharmaceuticals Inc., has a portfolio of currently marketed products
plus a pipeline of additional products under development by third
parties. For further information, please visit our web site:
www.accentia.net.

   About Exaeris, Inc.

   Exaeris is a wholly owned subsidiary of Inyx, located in Exton,
PA. Exaeris is the commercial arm of Inyx and markets a range of
respiratory products acquired through key strategic partnerships and
internal development.

   About Inyx, Inc.

   Inyx is a specialty pharmaceutical company with niche drug
delivery technologies and products for the treatment of respiratory,
allergy, dermatological, topical and cardiovascular conditions. Inyx
focuses its expertise on both prescription and over-the-counter
pharmaceutical products, and provides specialty pharmaceutical
development and production consulting services. In addition, Inyx is
developing its own proprietary products to be marketed by Exaeris and
strategic partners. The company's operations are conducted through
several other wholly owned subsidiaries, including: Inyx USA, Ltd.,
based in Manati, Puerto Rico; Inyx Pharma Ltd. and Inyx Europe
Limited, which owns and operates Ashton Pharmaceuticals Ltd., all near
Manchester, England; and Inyx Canada, Inc. in Toronto. Inyx, Inc.'s
corporate offices are in New York City. For more information, please
visit: www.inyxinc.com.

   Forward-Looking Statements

   Statements in this release that are not strictly historical in
nature constitute "forward-looking statements." Such statements
include, but are not limited to, statements about Accentia, Inyx,
their respective operations and any other statements relating to their
respective products, product candidates, regulatory approval, product
launches and product development programs. Such statements may
include, without limitation, statements with respect to each of the
Company's plans, objectives, expectations and intentions and other
statements identified by words such as "may," "could," "would,"
"should," "believes," "expects," "anticipates," "estimates,"
"intends," "plans" or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties, and other
factors that may cause the actual results of Accentia and/or Inyx to
be materially different from historical results or from any results
expressed or implied by such forward-looking statements. These factors
include, but are not limited to, risks and uncertainties related to
the progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining regulatory
approval for product candidates; competition from other pharmaceutical
or biotechnology companies; and the additional risks discussed in
Accentia's and Inyx's respective filings with the Securities and
Exchange Commission. All forward looking statements are qualified in
their entirety by this cautionary statement, and Accentia and Inyx
does not undertake any obligation to revise or update this news
release to reflect events or circumstances after the date hereof.